Skip to main content
SpringerLink
Log in

Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation

  • Letter to the editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Schmid C (2014) Proceedings from the National Cancer Institute’s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant 20(1):4–13

    Article  PubMed  Google Scholar 

  2. Leung AY, Tse E, Hwang YY, Chan TS, Gill H, Chim CS, Lie AK, Kwong YL (2013) Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. Am J Hematol 88(6):485–491

    Article  PubMed  Google Scholar 

  3. Jabbour E, O'Brien S, Ravandi F, Kantarjian H (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125(26):4010–4016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127(26):3312–3320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J med 375(8):740–753

    Article  CAS  PubMed  Google Scholar 

  6. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J med 376(9):836–847

    Article  PubMed  Google Scholar 

  7. Anwer F, Shaukat AA, Zahid U, Husnain M, McBride A, Persky D, Lim M, Hasan N, Riaz IB (2017) Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy 9(2):123–130

    Article  CAS  PubMed  Google Scholar 

  8. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hwang YY, Khong PL, Kwong YL (2017 Apr 22) Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol [Epub ahead of print]

  10. Au WY, Kwong YL, Lie AK, Ma SK, Liang R (1999) Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 17(2):45–52

    Article  CAS  PubMed  Google Scholar 

  11. Ma SY, Au WY, Ng IO, Lie AK, Leung AY, Liang R, Lau GK, Kwong YL (2004) Hepatitic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation 77(8):1252–1259

    Article  PubMed  Google Scholar 

  12. Ma SY, Au WY, Lie AK, Ng IO, Leung AY, Tse EW, Liang RH, Lau GK, Kwong YL (2004) Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation. Bone marrow transplant 34(1):57–61

    Article  CAS  PubMed  Google Scholar 

  13. Chan TS, Khong PL, Kwong YL (2016) Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol 95(11):1913–1915

    Article  PubMed  Google Scholar 

  14. Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471–2478

    Article  CAS  PubMed  Google Scholar 

  15. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P (2013) Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19(7):1059–1064

    Article  PubMed  Google Scholar 

  16. Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ (2013) Proceedings from the National Cancer Institute’s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part I. Biology of relapse after transplantation. Biol Blood Marow Transplant 19(11):1537–1545

    Article  Google Scholar 

  17. Chan TS, Khong PL, Kwong YL (2016) Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma. Ann Hematol 95(11):1917–1918

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Pokfulam, Road, Hong Kong

    Thomas S. Y. Chan, Joycelyn P. Y. Sim & Yok-Lam Kwong

Authors
  1. Thomas S. Y. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joycelyn P. Y. Sim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yok-Lam Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yok-Lam Kwong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, T.S.Y., Sim, J.P.Y. & Kwong, YL. Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation. Ann Hematol 96, 1569–1572 (2017). https://doi.org/10.1007/s00277-017-3033-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3033-7

Search

Navigation